RxDoctor Payments Data

Elise Juliano

Nurse Practitioner · Lawrence, MANPI 1508483231

Payments from drug & device makers

$1,428in general payments, 2019–2025

Across 72 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$977
  • Pfizer$258
  • SK Life Science, Inc.$72
  • Novartis$37
  • AstraZeneca$33
  • UCB, Inc.$30
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$1,20384%
  • Education$22516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)58$977
Pfizer6$258
SK Life Science, Inc.3$72
Novartis2$37
AstraZeneca1$33
UCB, Inc.1$30
Amgen1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,428 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$71,024
Medicare patients
366
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate117$157,385
QuliptaAtogepant54$66,770
UbrelvyUbrogepant30$32,824
Aimovig AutoinjectorErenumab-Aooe13$17,961
Memantine Hcl ErMemantine Hcl23$3,791
Donepezil Hcl159$1,433
Memantine Hcl35$1,149
Gabapentin101$1,019
Diclofenac Sodium17$796
Propranolol Hcl ErPropranolol Hcl31$686
Primidone26$630
Mirtazapine23$612
Sumatriptan Succinate12$584
Sertraline Hcl102$425
Atorvastatin Calcium25$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$258$157,385117 claims
AbbVieQulipta, Ubrelvy$977$99,59484 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →